Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims4
A method of entraining a patient suffering from Non-24-Hour Sleep-Wake Disorder to a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, wherein the patient is being treated with a beta-adrenergic receptor antagonist, the method comprising:
- discontinuing treatment with the beta-adrenergic receptor antagonist;
- and then
- administering to the patient with 20 mg tasimelteon once daily about one-half hour to about one-and-one-half hours before the target bedtime.
Dependencies are inferred from the claim text.